CSL eyes Andembry spot on paediatric HAE market amid positive Phase III results

Phase 3positiveAndembryTakhzyroOrladeyoPositive

AI Analysis

Summary

CSL announced positive Phase III results for Andembry in pediatric hereditary angioedema (HAE), positioning the drug to compete with market leaders Takhzyro and the newer oral option Orladeyo.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Importance:6/10

Sentiment:

0.70

Phase 3Hereditary AngioedemaPediatric indicationPositive trial results

Related Companies

$OPTN $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on July 28, 2026 10:03 AM

Read Original